During the corresponding time, Seer Inc saw a revenue deteriorated by -0.29 % year on year, sequentially revenue grew by 56.51 %. While revenue at the Seer Inc 's corporate clients
Balanced Analysis of Seer s New Partnership Amid Financial Challenges In a strategic move aimed at revolutionizing the field of proteomics, Seer Inc. has entered into a co-marketing and sales agreement with Thermo Fisher Scientific. This collaboration promises unprecedented access to deep, unbiased proteomics at scale, which could potentially unlock new dimensions in human biology research. The announcement of this partnership signifies a pivotal moment for Seer as it endeavors to enhance its technological capabilities and market reach. Collaborative Benefits The agreement positions Seer to leverage Thermo Fisher s extensive marketing channels and sales expertise, expanding the accessibility of Seer s cuttin...
Understanding the Future of Cancer Detection: Seer s Groundbreaking Technological Integration In a monumental stride within the landscape of biomedical research, Seer Technology Access Center has unveiled data from PrognomiQs early cancer detection study, strongly highlighting the efficacy of their Proteograph XT Assay. This advancement, coupled with the implementation of the Thermo Scientific Orbitrap Astral Mass Spectrometer, has accomplished something truly unprecedented identifying over 13,000 protein groups across a comprehensive study involving 2,840 subjects. The implications of this achievement are multifaceted, touching upon early diagnosis, personalized medicine, and even the progression towards pr...
In the pursuit of breakthrough drug development and the identification of effective biomarkers, the field of proteogenomics has gained significant momentum. In recent years, Weill Cornell Medicine spearheaded a remarkable study that utilized the innovative Seer Proteograph technology to enable unprecedented genetic marker mapping for proteogenomics research. This scientific endeavor sheds light on the identification of protein-altering variants, paving the way for population-scale protein quantitative trait loci (pQTL) studies. This article delves into the fascinating details of this study and highlights the far-reaching implications for drug development and precision medicine.Mapping the Potential:The Seer ...
Sources:
Seer Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Seer Inc’s corporate clients.
For your research, we’ve provided 9 tables on Seer Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1.81 %